节点文献

219例弥漫性大B细胞淋巴瘤免疫表型及遗传学特征分析

Immunophenotypes and Cytogenetic Alterations in 219 Cases of Diffuse Large B-cell Lymphoma

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 管冰心潘毅房爱菊梁艳霍颖颖孙保存王华庆付凯孟斌

【Author】 Bingxin GUAN 1,Yi PAN 2,Aiju FANG 3,Yan LIANG 1,Yingying HUO 1,Baocun SUN 2,Huaqing WANG 2,Kai FU (2,4),Bin MENG 1 1 Department of Pathology,Shandong University School of Medicine,Ji’nan 250012,China 2 Departments of Pathology and Lymphoma,Tianjin Medical University Cancer Institute and Hospital,Key Laboratory of Cancer Prevention and Therapy,Sino-American Center for Lymphoma Diagnosis and Therapy,Tianjin 300060,China 3 Department of Pathology,Shandong Jiaotong Hospital,Jinan 250031,China 4 Department of Pathology and Microbiology,983135 Nebraska Medical Center,University of Nebraska Medical Center,Omaha,NE 68198-3135

【机构】 山东大学医学院病理学教研室天津医科大学附属肿瘤医院病理科,中美淋巴血液肿瘤诊治中心山东省交通医院病理科美国内布拉斯加大学医学中心病理学与微生物学系,中美淋巴血液肿瘤诊治中心

【摘要】 目的:探讨国内弥漫性大B细胞淋巴瘤(DLBCL)免疫表型分型及BCL-2和BCL-6基因异常的分布情况。方法:应用组织芯片和免疫组织化学法及FISH技术对219例DLBCL的免疫表型及BCL-2和BCL-6基因异常进行检测,根据Hans法进行分型;并收集国内7家相关研究报道,进行综合分析。结果:本组研究结果:219例DLBCL中,非GCB型(165例,75.3%)显著高于GCB型(54例,24.7%)(P<0.001)。BCL-2基因异常共49例(25.8%),其中t(14;18)5例(2.6%)均为GCB型;BCL-2基因扩增44例(23.2%),GCB型4例(8.5%),非GCB型40例(28.0%),有显著性差异(P=0.013)。BCL-6基因重排共42例(22.1%),GCB型7例(14.9%),非GCB型35例(24.5%),差异无统计学意义(P=0.189)。BCL-2基因扩增和BCL-6基因重排呈显著负相关(r=-0.180,P=0.013) 8组综合分析:1 259例中非GCB型(879例,69.8%)明显高于GCB型(380例,30.2%)(P<0.001);免疫表型中CD10和MUMl阳性率组间差异较小(P=0.047和P=0.048),而BCL-6及BCL-2阳性率组间存在明显差异(P<0.001)。结论:我国DLBCL患者在主要免疫表型和遗传学特征方面具有独特性,对此值得进行深入研究。

【Abstract】 Objective:To investigate the immunophenotypes,subtypes based on Hans algorithm,and alterations of Bcl-2 and Bcl-6 gene in diffuse large B-cell lymphoma(DLBCL) from Chinese patients.Methods:The expression of CD10,BCL-6,MUM1,BCL-2,Ki67 and other markers were detected by immunohistochemistry in tissue microarrays of 219 DLBCL cases.Hans algorithm was applied to classify DLBCL into GCB and non-GCB subtypes.Interphase fluorescence in situ hybridization(FISH ) was used to detect the incidence of Bcl-2 and Bcl-6 gene alterations.Other seven studies published in the last two years on DLBCL from China were collected and analyzed.Results: (1) This study:①of 219 DLBCL cases,non-GCB subtype(165 cases,75.3%) was significantly more common than GCB subtype(54 cases,24.7%)(P<0.001 ).②Bcl-2 gene alteration was detected in 49 cases(25.8%),including 5 cases with the t(14;18 )(2.6%) which all existed in GCB subtype,and 44 cases of Bcl-2 amplification(23.2%) which existed in GCB subtype in 4 cases(8.5%) and in non-GCB subtype in 40 cases(28.0%)(P = 0.013).③Bcl-6 gene rearrangement was detected in 42 cases(22.1%),which was in GCB in 7 cases(14.9%) and was in non-GCB in 35 cases(24.5%)(P = 0.189).④a significant negative correlation between Bcl-2 gene amplification and Bcl-6 gene rearrangement was seen(r = - 0.179 6,P = 0.016 8 ).Amongst 5 cases having the t(14;18 ) translocation, 2 cases accompanied by Bcl-6 gene rearrangement.Forty-nine cases with Bcl-2 gene alterations including translocation and amplification were all but one expressing BCL-2 protein,and there was no significant association between Bcl-6 gene rearrangement and BCL-6 protein expression(P = 0.726 ).⑤there was no significant difference between nodal and extranodal DLBCLs in immunophenotypes,subtypes based on Hans algorithm,and Bcl-2 and Bcl-6 gene alterations(P = 0.462,P = 0.426 and P = 0.167 ).(2) Comprehensive analysis of eight studies: of the total 1,259 cases,non-GCB subtype(879 cases,69.8%) was significantly more common than GCB subtype(380 cases,30.2%) (P<0.001 ).Conclusion:There are some distinctive features on immunophenotypes and cytogenetic alterations in DLBCL of Chinese patients,which need elucidation by more studies.

  • 【文献出处】 中国肿瘤临床 ,Chinese Journal of Clinical Oncology , 编辑部邮箱 ,2012年12期
  • 【分类号】R733.1
  • 【被引频次】9
  • 【下载频次】189
节点文献中: 

本文链接的文献网络图示:

本文的引文网络